- Home
- RDHL vs SYRS Comparison
RDHL vs SYRS Comparison
Compare RDHL & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- SYRS
- Stock Information
- Founded
- RDHL 2009
- SYRS 2011
- Country
- RDHL Israel
- SYRS United States
- Employees
- RDHL N/A
- SYRS N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- SYRS Health Care
- Exchange
- RDHL Nasdaq
- SYRS Nasdaq
- Market Cap
- RDHL 8.6M
- SYRS 7.1M
- IPO Year
- RDHL N/A
- SYRS 2016
- Fundamental
- Price
- RDHL $6.99
- SYRS $0.21
- Analyst Decision
- RDHL
- SYRS Hold
- Analyst Count
- RDHL 0
- SYRS 5
- Target Price
- RDHL N/A
- SYRS $3.00
- AVG Volume (30 Days)
- RDHL 21.2K
- SYRS 3.5M
- Earning Date
- RDHL 12-27-2024
- SYRS 10-31-2024
- Dividend Yield
- RDHL N/A
- SYRS N/A
- EPS Growth
- RDHL N/A
- SYRS N/A
- EPS
- RDHL N/A
- SYRS N/A
- Revenue
- RDHL $3,707,000.00
- SYRS $386,000.00
- Revenue This Year
- RDHL $224.90
- SYRS N/A
- Revenue Next Year
- RDHL $82.69
- SYRS $1,011.11
- P/E Ratio
- RDHL N/A
- SYRS N/A
- Revenue Growth
- RDHL N/A
- SYRS N/A
- 52 Week Low
- RDHL $6.35
- SYRS $0.18
- 52 Week High
- RDHL $43.50
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- RDHL 42.91
- SYRS 29.09
- Support Level
- RDHL $7.09
- SYRS $0.20
- Resistance Level
- RDHL $7.44
- SYRS $0.26
- Average True Range (ATR)
- RDHL 0.53
- SYRS 0.02
- MACD
- RDHL -0.03
- SYRS 0.07
- Stochastic Oscillator
- RDHL 12.36
- SYRS 11.39
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.